Blog Archives
Long-term treatment with leuprorelin for SBMA
This natural history-controlled study evaluated the prognosis and progression of spinal and bulbar muscular atrophy (SBMA), a rare X-linked motor neuron disorder caused by trinucleotide repeat expansion in the AR (androgen receptor) gene, after long-term androgen suppression with leuprorelin acetate treatment. A total of 36 patients with SBMA were treated with leuprorelin acetate for up … [Read more]
Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy
GNE myopathy is a rare, autosomal recessive, inborn error of sialic acid metabolism, caused by mutations in GNE, the gene encoding UDP-N-acetyl-glucosamine-2-epimerase/N-acetylmannosamine kinase. The disease manifests as an adult-onset myopathy characterized by progressive skeletal muscle weakness and atrophy. There is no medical therapy available for this debilitating disease. Hyposialylation of muscle glycoproteins likely contributes to … [Read more]
Novel clinical and pathological features in cystinosis distal myopathy
Nephropathic cystinosis is an autosomal recessive lysosomal disease in which cystine cannot exit the lysosome to complete its degradation in the cytoplasm, thus accumulating in tissues. Some patients develop a distal myopathy involving mainly hand muscles. Myopathology descriptions from only 5 patients are available in the literature. Here, the authors present a comprehensive clinical, … [Read more]
A defect in myoblast fusion underlies Carey-Fineman-Ziter syndrome
Multinucleate cellular syncytial formation is a hallmark of skeletal muscle differentiation. Myomaker, encoded by Mymk (Tmem8c), is a well-conserved plasma membrane protein required for myoblast fusion to form multinucleated myotubes in mouse, chick, and zebrafish. This multinational study reports that autosomal recessive mutations in MYMK (OMIM 615345) cause Carey-Fineman-Ziter syndrome in humans (CFZS; OMIM … [Read more]
Tricyclo-DNA antisense oligonucleotide treatment: A promising systemic alternative for treating SMA
Spinal muscular atrophy (SMA) is a recessive disease caused by mutations in the SMN1 gene, which encodes the protein survival motor neuron (SMN), whose absence dramatically affects the survival of motor neurons. In humans, the severity of the disease is lessened by the presence of a gene copy, SMN2. SMN2 differs from SMN1 by a … [Read more]
Gene therapy: Microdystrophin restores muscle strength in DMD
Researchers from Genethon and the Institute of Myology, AFM-Téléthon laboratories, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy in the treatment of Duchenne muscular dystrophy. Indeed, after injecting microdystrophin (a “shortened” version of the dystrophin gene) via a drug vector, the researchers managed to … [Read more]
Wide spectrum of clinical severity in affected female carriers of MTM1 mutations
X-linked myotubular myopathy (XLMTM), a severe congenital myopathy, is caused by mutations in the MTM1 gene located on the X chromosome. A majority of affected males die in the early postnatal period, whereas female carriers are believed to be usually asymptomatic. Nevertheless, several affected females have been reported. To assess the phenotypic and pathological spectra … [Read more]
Evaluation of physical activity by accelerometry: a promising measure in patients with neuromuscular pathology
Clinicians and researchers at the Institute of Myology have just published an article in the journal Neurology* concerning the use of accelerometers to assess the impact of a treatment by measuring the daily physical activity of patients with idiopathic inflammatory myopathies (IIM). Jean-Yves Hogrel, Director of the Laboratory of Physiology and Neuromuscular Evaluation, discusses the … [Read more]
Coexistence of autoantibodies in myasthenia gravis associated with invasive thymoma
This study describes two cases of myasthenia gravis (MG) with double seropositivity for acetylcholine receptor (AChR) and low-density lipoprotein receptor-related protein 4 (LRP4) antibodies (AChR/LRP4-MG) with invasive thymoma. Both cases showed myasthenic weakness, which was restricted to the ocular muscles for >5 months from onset, and then unprovoked severe clinical deterioration supervened with predominant … [Read more]
A multi-source approach to determine SMA incidence and research ready population
In spinal muscular atrophy (SMA), degeneration of motor neurons causes progressive muscular weakness, which is caused by homozygous deletion of the SMN1 gene. Available epidemiological data on SMA are scarce, often outdated, and limited to relatively small regions or populations. Combining data from different sources including genetic laboratories and patient registries may provide better insight … [Read more]